Patents by Inventor Günter Sprotte

Günter Sprotte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PREDICTIVE BIOMARKERS OF CLINICAL RESPONSE TO ANTI-LPS IMMUNOGLOBULIN TREATMENT
    Publication number: 20190219594
    Abstract: The present invention relates to the biomarkers for predicting the clinical response to anti-LPS immunoglobulin treatments in patients in need thereof. In particular, the invention provides methods for predicting the clinical response to an anti-LPS immunoglobulin treatment in a patient in need thereof, said method comprising the steps of evaluating the expression of a predictive biomarker selected from the group consisting of CD14, CD68, TLR4, TLR7, IL6, IL8, IL10, IFN-alpha, IGF1, CXCL1, CXCL9, CXCL10, RAGE, GDNF, BCHE, and combination thereof, in said patient.
    Type: Application
    Filed: February 22, 2019
    Publication date: July 18, 2019
    Inventors: Günter SPROTTE, Ana Maria WAAGA-GASSER
  • Predictive biomarkers of clinical response to anti-LPS immunoglobulin treatment
    Patent number: 10261095
    Abstract: The present invention relates to the biomarkers for predicting the clinical response to anti-LPS immunoglobulin treatments in patients in need thereof. In particular, the invention provides methods for predicting the clinical response to an anti-LPS immunoglobulin treatment in a patient in need thereof, said method comprising the steps of evaluating the expression of a predictive biomarker selected from the group consisting of CD14, CD68, TLR4, TLR7, IL6, IL8, IL10, IFN-alpha, IGF1, CXCL1, CXCL9, CXCL10, RAGE, GDNF, BCHE, and combination thereof, in said patient.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: April 16, 2019
    Assignees: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG, IGNOVA GMBH
    Inventors: Günter Sprotte, Ana Maria Waaga-Gasser
  • PREDICTIVE BIOMARKERS OF CLINICAL RESPONSE TO ANTI-LPS IMMUNOGLOBULIN TREATMENT
    Publication number: 20180080943
    Abstract: The present invention relates to the biomarkers for predicting the clinical response to anti-LPS immunoglobulin treatments in patients in need thereof. In particular, the invention provides methods for predicting the clinical response to an anti-LPS immunoglobulin treatment in a patient in need thereof, said method comprising the steps of evaluating the expression of a predictive biomarker selected from the group consisting of CD14, CD68, TLR4, TLR7, IL6, IL8, IL10, IFN-alpha, IGF1, CXCL1, CXCL9, CXCL10, RAGE, GDNF, BCHE, and combination thereof, in said patient.
    Type: Application
    Filed: April 14, 2016
    Publication date: March 22, 2018
    Applicants: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG, IGNOVA GMBH
    Inventors: Günter SPROTTE, Ana Maria WAAGA-GASSER
  • Use of an agent consisting of antibodies and/or insulin-like growth factor antagonists
    Patent number: 9913904
    Abstract: The present invention relates to the use of a composition selected from the group consisting of antibodies, antibody fragments, insulin-like growth factor antagonists, Toll-like receptor antagonists and mixtures thereof for the treatment or the prophylaxis of certain diseases.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: March 13, 2018
    Assignee: IGNOVA GMBH
    Inventors: Jan Wesjohann, Günter Sprotte, Ana Maria Waaga-Gasser
  • Use of an agent consisting of antibodies and/or insulin-like growth factor antagonists
    Patent number: 9801938
    Abstract: The present invention relates to the use of a composition selected from the group consisting of antibodies, antibody fragments, insulin-like growth factor antagonists, Toll-like receptor antagonists and mixtures thereof for the treatment or the prophylaxis of certain diseases.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: October 31, 2017
    Assignees: MAT-MALTA ADVANCED TECHNOLOGIES LIMITED, FREISTAAT BAYERN REPRESENTED BY JULIUS-MAXIMILLIANS-UNIVERSITÄT WÜRZBURG
    Inventors: Jan Wesjohann, Günter Sprotte, Ana Maria Waaga-Gasser
  • USE OF AN AGENT CONSISTING OF ANTIBODIES AND/OR INSULIN-LIKE GROWTH FACTOR ANTAGONISTS
    Publication number: 20170252438
    Abstract: The present invention relates to the use of a composition selected from the group consisting of antibodies, antibody fragments, insulin-like growth factor antagonists, Toll-like receptor antagonists and mixtures thereof for the treatment or the prophylaxis of certain diseases.
    Type: Application
    Filed: February 15, 2017
    Publication date: September 7, 2017
    Inventors: Jan Wesjohann, Günter Sprotte, Ana Maria Waaga-Gasser
  • USE OF AN AGENT CONSISTING OF ANTIBODIES AND/OR INSULIN-LIKE GROWTH FACTOR ANTAGONISTS
    Publication number: 20140112937
    Abstract: The present invention relates to the use of a composition selected from the group consisting of antibodies, antibody fragments, insulin-like growth factor antagonists, Toll-like receptor antagonists and mixtures thereof for the treatment or the prophylaxis of certain diseases.
    Type: Application
    Filed: March 28, 2012
    Publication date: April 24, 2014
    Applicants: FREISTAAT BAYERN REPRESENTED BY JULIUS- -MAXIMILIANS-UNIVERSITAT WURZBURG, MAT-MALTA ADVANCED TECHNOLOGIES LIMITED
    Inventors: Jan Wesjohann, Günter Sprotte, Ana Maria